-+ 0.00%
-+ 0.00%
-+ 0.00%

2026 ASCO | INNOVENT PRESENTS LONG-TERM FOLLOW-UP RESULTS FROM THE POC STUDY OF IBI363 (TAK-928) (PD-1/IL-2Α-BIAS BISPECIFIC FUSION PROTEIN), SHOWING ROBUST SURVIVAL BENEFITS IN ADVANCED IMMUNOTHERAPY-RESISTANT NON-SMALL CELL LUNG CANCER

路透·06/01/2026 00:00:08

登錄查看新聞詳情